{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-21-001525","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.219437+00:00","generated_at":"2026-06-28T14:02:42.665359+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Summit Therapeutics appoints Dr. Urte Gayko to Board of Directors","bullets":["Dr. Urte Gayko appointed to Summit's Board effective Nov 3, 2021; will serve on Nominating and Corporate Governance Committee.","Gayko is SVP of Drug Development & Regulatory Affairs at Nektar Therapeutics; previously Global Head of Regulatory at Pharmacyclics.","Over 20 years experience in regulatory and clinical development across Amgen, AbbVie, and biotech; PhD in molecular/cellular biology from Harvard.","She received an option grant under Summit's non-employee director compensation policy; also standard indemnification agreement.","Board determined Gayko qualifies as independent director under Nasdaq listing rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-21-001525","json":"https://secwatch.observer/filing/0001193805-21-001525.json","markdown":"https://secwatch.observer/filing/0001193805-21-001525.md","text":"https://secwatch.observer/filing/0001193805-21-001525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000119380521001525/0001193805-21-001525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000119380521001525/e621052_8k-summit.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T14:02:42.665359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68b6fb5dfc","claim":"Urte Gayko was elected as director at Summit Therapeutics Inc..","evidence_excerpt":"Effective on November 3, 2021, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Urte Gayko as a director of the Company, to occupy a newly created seat on the Board and (ii) the appointment of Dr. Gayko to serve on the Nominating and Corporate Governance Committee.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000119380521001525/0001193805-21-001525-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}